Dulaglutide biosimilar - Shandong Boan Biotechnology
Alternative Names: BA 5101; LY-05008; Trulicity biosimilar - Luye Pharma Group; Trulicity® biosimilarLatest Information Update: 21 Jul 2025
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antihyperglycaemics; Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 21 Jul 2025 FDA approves IND application for Dulaglutide biosimilar in Type 2 diabetes mellitus for rest of the world, prior to July 2025 (Shandong Boan Biotechnology pipeline, July 2025)
- 27 Mar 2024 Luye Pharma announces intention to submit BLA to NMPA for Type 2 diabetes mellitus in China
- 27 Mar 2024 Shandong Boan Biotechnology completes phase III trial for Type 2 diabetes mellitus in China (SC)